Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

TransMedics Group (TMDX), Everus (ECG), and Excelerate Energy (EE) reported significant sales beats in their recent earnings releases, leading to substantial stock price increases. TMDX's Q1 2025 sales exceeded expectations by 16%, driving a near 20% share price increase, while ECG's revenue beat of over 22% led to a 17% jump in its stock, supported by a 41% increase in its order backlog driven by data center demand. EE's Q1 sales surpassed estimates by over 51%, resulting in a 10% stock increase, though concerns remain about potential LNG oversupply in the future.

Analysis

Three mid-cap companies—TransMedics Group (TMDX), Everus (ECG), and Excelerate Energy (EE)—demonstrated significant outperformance in May, reporting substantial sales beats that catalyzed notable share price increases, underscoring opportunities within less-covered market segments. TransMedics Group announced Q1 2025 sales of $143 million, surpassing analyst expectations by 16% and achieving 48% year-over-year revenue growth, well above the forecasted 27%. This performance, coupled with adjusted EPS more than double expectations at $0.70, led to an almost 20% stock surge and an increased full-year revenue guidance to $575 million, implying 30% growth over 2024; however, the stock remains approximately 20% below its August 2024 peak and has a history of volatility, with current analyst consensus price targets suggesting a 12.44% downside from its June 10 price. Everus reported Q1 revenue of nearly $827 million, a 22% beat, translating to 32% sales growth—four times the anticipated rate—and a 31% increase in non-adjusted EPS to $0.72, contrasting with expectations of a decline. Its stock rose 17%, supported by a robust 41% increase in its order backlog to $3.1 billion, largely driven by data center construction demand, with analysts like Stifel Nicolaus raising targets and the average forecast implying 16% upside. Excelerate Energy's Q1 sales reached $315 million, exceeding estimates by over 51% and delivering 57% revenue growth, far outpacing the expected 4%; its shares climbed 10%. While Jefferies initiated coverage with a bullish $39 target based on LNG demand and future contract potential, broader market concerns persist regarding a potential LNG supply glut by 2030, which could pressure prices and temper Excelerate's growth trajectory, reflected in a 'Hold' consensus rating with minimal upside from current levels.

Key Decisions for Investors

• For TransMedics Group, investors should weigh its strong Q1 earnings and upwardly revised guidance against its historical share price volatility and current analyst price targets which suggest potential overvaluation following the recent rally.
• Everus's significant sales outperformance, coupled with a 41% surge in its order backlog primarily from data center projects and positive analyst revisions, indicates strong growth prospects and warrants consideration for exposure to the expanding data infrastructure sector.
• Investors considering Excelerate Energy should carefully balance its impressive Q1 sales growth and the optimistic outlook from some analysts regarding LNG demand against the material long-term risk of LNG oversupply, which could adversely affect future profitability.
• The notable earnings surprises from these mid-cap companies highlight the potential for alpha generation in less-analyzed market segments; however, thorough due diligence on individual company fundamentals, sector-specific risks, and valuation is crucial before making investment decisions.